Development of gliadin-specific immune responses in children with HLA-associated genetic risk for celiac disease by Lammi, Anne et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=igas20
Download by: [University of Helsinki] Date: 04 May 2016, At: 00:08
Scandinavian Journal of Gastroenterology
ISSN: 0036-5521 (Print) 1502-7708 (Online) Journal homepage: http://www.tandfonline.com/loi/igas20
Development of gliadin-specific immune
responses in children with HLA-associated genetic
risk for celiac disease
Anne Lammi, Pekka Arikoski, Arja Hakulinen, Ursula Schwab, Matti
Uusitupa, Seppo Heinonen, Erkki Savilahti, Tuure Kinnunen & Jorma Ilonen
To cite this article: Anne Lammi, Pekka Arikoski, Arja Hakulinen, Ursula Schwab, Matti
Uusitupa, Seppo Heinonen, Erkki Savilahti, Tuure Kinnunen & Jorma Ilonen (2016)
Development of gliadin-specific immune responses in children with HLA-associated genetic
risk for celiac disease, Scandinavian Journal of Gastroenterology, 51:2, 168-177, DOI:
10.3109/00365521.2015.1067328
To link to this article:  http://dx.doi.org/10.3109/00365521.2015.1067328
Published online: 10 Jul 2015.
Submit your article to this journal 
Article views: 181
View related articles 
View Crossmark data
Scandinavian Journal of Gastroenterology. 2016; 51: 168
ORIGINAL ARTICLE
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Abstract
Objective. The development of gliadin-speciﬁc antibody and T-cell responses were longitudinally monitored in young
children with genetic risk for celiac disease (CD).Material andmethods. 291 newborn children positive for HLA-DQB1*02
and -DQA1*05 alleles were followed until 3–4 years of age by screening for tissue transglutaminase autoantibodies (tTGA) by
using a commercial ELISA-based kit and antibodies to deamidated gliadin peptide (anti-DGP) by an immunoﬂuorometric
assay. Eighty-ﬁve of the children were also followed for peripheral blood gliadin-speciﬁc CD4+ T-cell responses by using a
carboxyﬂuorescein diacetate succinimidyl ester-based in vitro proliferation assay. Results. The cumulative incidence of tTGA
seropositivity during the follow-up was 6.5%. CD was diagnosed in nine of the tTGA-positive children (3.1%) by duodenal
biopsy at a median 3.5 years of age. All of the children with conﬁrmed CDwere both IgA and IgG anti-DGP positive at the time
of tTGA seroconversion and in over half of the cases IgG anti-DGP positivity even preceded tTGA seroconversion.
Peripheral blood T-cell responses to deamidated and native gliadin were detected in 40.5% and 22.2% of the children at
the age of 9 months and these frequencies decreased during the follow-up to the levels of 22.2% and 8.9%, respectively.
Conclusions. Anti-DGP antibodies may precede tTGA seroconversion and thus frequent monitoring of both tTGA and
anti-DGP antibodies may allow earlier detection of CD in genetically susceptible children. Peripheral blood gliadin-speciﬁc
T-cell responses are relatively common in HLA-DQ2-positive children and are not directly associated with the development
of CD.
Key Words: antibodies to deamidated gliadin peptide, celiac disease, children, gliadin-speciﬁc T cells, tissue transglutaminase
antibodies
Introduction
Celiac disease (CD) is a chronic T-cell-mediated
autoimmune enteropathy induced by dietary gluten
in genetically susceptible individuals. Over 90% of
CD patients express the HLA-DQ2 molecule
encoded by the HLA-DQA1*05 and -DQB1*02
alleles [1,2]. Most of the remaining patients express
either the HLA-DQ8 molecule encoded by the
DQA1*03 and DQB1*0302 alleles, or have at least
one of the two alleles forming the risk-associated
DQ2 molecule, DQB1*02 or DQA1*05 allele [3].
The risk for CD is further increased by carrying
two copies of the HLA-DQ2-encoding alleles,
Correspondence: Anne Lammi, MD, Department of Clinical Microbiology, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland,
P.O. Box 1627, FI-70211 Kuopio, Finland. Tel: +35 84 4578 8023. E-mail: anne.lammi@uef.ﬁ
(Received 27 April 2015; revised 23 June 2015; accepted 24 June 2015)
ISSN 0036-5521 print/ISSN 1502-7708 online  2015 Informa Healthcare
DOI: 10.3109/00365521.2015.1067328
6 8 6 8–177
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
els
ink
i] 
at 
00
:09
 04
 M
ay
 20
16
 
emphasizing the role of HLA-DQ2 as the most impor-
tant immunogenetic factor [4,5]. The prevalence of
CD is approximately 1% in Western Europe and
North America but screening studies suggest
signiﬁcantly higher prevalence rates than what is
observed when the diagnosis is made by clinical
suspicion [6–8]. Currently, the screening of CD is
based on IgA class tissue transglutaminase autoanti-
body (tTGA) measurement and the diagnosis is con-
ﬁrmed by the typical histological changes, crypt
hyperplasia and villous atrophy observed in the
duodenal biopsy of small intestine [9]. Recently
proposed new criteria by The European Society for
Paediatric Gastroenterology, Hepatology and Nutri-
tion, however, suggest that the diagnosis of CD in
symptomatic children can be based on high levels
of CD-speciﬁc antibodies reducing the need for
duodenal biopsy [10].
Although the screening of CD has been for some
time based on the measurement of IgA class tTGA, it
has been demonstrated that especially IgG-class anti-
bodies to deamidated gliadin peptide (anti-DGP)
may appear earlier than tTGA-seropositivity in
genetically susceptible children [11,12]. This is in
accordance with the suggested signiﬁcance for T-cell
responses to DGPs in the intestinal mucosa in the
initiation of the disease process [13]. Detection of
T-cell responses to deamidated gliadin in the periph-
eral blood is an interesting concept for monitoring
CD-related immunity, since their emergence might
even precede the antibody response to gliadin
peptides, and thus they could be used as the ﬁrst
detectable marker of the disease process. In several
studies, T cells speciﬁc to deamidated gliadin have
been demonstrated in the circulation of adult
patients with CD as a marker of active disease pro-
cess, most commonly after oral gluten challenge
[14–16]. Recently, we were able to demonstrate
the presence of T cells speciﬁc to deamidated gliadin
in the peripheral blood of children with active CD
without gluten challenge [17]. Circulating T cells
speciﬁc to various DGPs were also detected in a high
percentage of children with newly diagnosed CD by
Liu et al. [18].
The aim of this study was to monitor the develop-
ment of gliadin-speciﬁc antibody and T-cell responses
in children genetically at-risk for CD and to evaluate
whether these responses can be detected before the
clinical onset of the disease. For this, we prospectively
followed newborn children carrying the high risk-
associated combination of HLA-DQB1*02 and
-DQA1*05 alleles (HLA-DQ2) until 3–4 years of
age by screening for tTGA and anti-DGP antibodies
as well as by assessing gliadin-speciﬁc CD4+ T-cell
responses in the peripheral blood.
Materials and methods
Study design
The current follow-up study was performed in a
cohort of Finnish children with a high genetic risk
for CD (recruited at the Kuopio University Hospital
and the Kätilöopisto Maternity Hospital in Helsinki).
Parents of newborn children were ﬁrst met at the
Maternity Hospital and the study protocol was brieﬂy
described to them. If the family decided to participate
in the study the cord blood sample of the newborn was
analyzed for the presence of HLA-DQ2, as described
earlier [19,20]. The result of the HLA-screening was
informed to the families by a phone call when the
child was 1–2 weeks old. Written informed consent
was obtained from all families. Families also partic-
ipated in a study where special nutritional counseling
was given to half of the families with the purpose to
optimize the introduction of gluten into a time-
window between 4 and 6 months age together with
ongoing breast feeding. No signiﬁcant effect of the
counseling for these parameters was detected. The
study plan was accepted by the ethics committee of
the Kuopio University Hospital.
A total of 2013 children were screened for risk-
associated HLA-DQ2. Altogether 339 of the children
(16.8%) were positive for HLA-DQ2 and ﬁnally
291 children continued in the follow-up study
(Figure 1). Blood samples were collected from the
children at the ages of 9, 12, 18, 24 and 36 months,
and also at 48 months for the children who reached
that age during the follow-up. Sera were analyzed for
tTGA and anti-DGP antibodies. Eighty-ﬁve children
(from the Kuopio University Hospital cohort) were
additionally followed for circulating gliadin-speciﬁc
T-cell responses until 48 months of age. Results of the
tTGA tests were reported to the participating families
and the parents of tTGA-seropositive children were
offered a possibility to undergo duodenal biopsy to
conﬁrm the diagnosis of CD. In 7 of the 10 cases
where duodenal biopsy was performed the child had a
high tTGA level (>10 times the upper limit of normal,
median 100, range 8.2–100) [10]. The ﬁnal diagnosis
was based on typical histological ﬁndings, villous
atrophy and crypt hyperplasia, in the duodenal biopsy
of small intestine detected in all children with a
diagnosis of CD [9].
Antibody assays
All collected serum samples were kept frozen at –80C
until analyses. Anti-DGP antibodies were measured
by using the time-resolved immunoﬂuorometric assay
(TR-IFMA), which allows the simultaneous detection
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of IgA and IgG class antibodies to a synthetic peptide,
derived from gamma gliadin of wheat [21]. The cut-
off value used for positivity was 153 for IgA and
119 for IgG class anti-DGP antibodies, as determined
earlier [12]. A commercial ELISA-based kit was used
for measuring tTGA (EliA Celikey, Phadia, Freiburg,
Germany). Values >8 U/ml were considered positive,
as suggested by the manufacturer. Only IgA class
tTGA was measured.
T-cell proliferation assay using the CFSE dilution
method
Peripheral blood mononuclear cells (PBMC) were
isolated from heparinized venous blood and labeled
with carboxyﬂuorescein diacetate succinimidyl ester
(CFSE) (Invitrogen, Molecular Probes, Carlsbad,
CA, USA) in order to detect cell proliferation, as
described in detail earlier [17]. Labeled PBMCs
were suspended in culture medium at 106/ml and
stimulated with various antigens in a volume of
200 ml in 96-well round-bottomed plates (Costar,
Corning Incorporate, Corning, NY, USA).
Deamidated gliadin (gTG; 20 mg/ml) was prepared
by incubation with tissue transglutaminase (tTG), as
described earlier [17]. Native gliadin alone was used
at a ﬁnal concentration of 10 mg/ml and tTG at 2 mg/
ml. Puriﬁed tetanus toxoid (TT, National Institute of
Health andWelfare, Helsinki, Finland) was used as an
independent control antigen at a ﬁnal concentration
of 1 mg/ml and puriﬁed phytohaemagglutinin (PHA,
Remel, UK) as an independent mitogen control of
cell functionality at 2 mg/ml. Cell cultures were main-
tained at 37C in a 5% CO2 incubator in 6–8 equal
wells, PHA in 2–4 equal wells. After 10 days of
culture, replicates for each antigen were pooled,
washed with ice-cold wash buffer (phosphate
buffered saline, 2% fetal calf serum and 0.1%
NaN3) and stained with the following antibodies:
anti-CD4-PerCP-Cy5.5, anti-CD45RO-PE-Cy7,
anti-CD45RA-APC and integrin b7-PE (BD Phar-
mingen, San Jose, CA, USA). Staining for cell surface
markers was carried out on ice in the dark for 20 min,
followed by two washes. The samples were analyzed
on a FACS Canto II ﬂow cytometer (BD, Mountain
View, CA, USA). CD4+ T-cell proliferation was
Figure 1. Study design. Children positive for HLA-DQB1*02 and -DQA1*05 alleles were prospectively followed for the emergence of tissue
transglutaminase autoantibody (tTGA) seropositivity and development of celiac disease until the age of 48 months.
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measured by determining the percentage of CFSElow
cells within the CD4+ T-cell fraction. The cell divi-
sion index (CDI) was calculated as follows: percent-
age of CD4+CFSElow cells in cultures stimulated
with antigen/CD4+CFSElow cells in cultures without
antigen [22]. Individual responses to an antigen were
considered positive when the CDI was ‡2.0 and the
difference in the percentage of CD4+CFSElow cells
between stimulated and unstimulated cultures was at
least 0.5%.
Figure 2. (A) The frequency of positive peripheral blood CD4+ T-cell responses to gTG and native gliadin decreased during the follow-up.
(B) The percentage of memory phenotype (CD45RA-CD45RO+) cells within the CD4+ CFSElow population in cultures stimulated with gTG.
(C) The percentage of b7-integrin expressing cells within proliferating memory CD4+ T cells stimulated with gTG, gliadin and TT.
Deamidated gliadin (gTG), native gliadin (Gliadin), tetanus toxoid (TT). *p < 0.05. All the statistical analyses were conducted by using the
Mann–Whitney U-test.
Table I. The frequency of peripheral blood T-cell responses to deamidated gliadin (gTG), gliadin, tissue transglutaminase (tTG) and tetanus
toxoid (TT) at different time points in all tested children (n = 85), as assessed by the CFSE dilution method.
Age (months)
Frequency of positive T-cell responses (%)
gTG Gliadin tTG TT
9 17/42 (40.5%)* 8/40 (20.0%) 2/30 (6.7%) 26/32 (81.3%)
12 18/56 (32.1%)* 9/55 (16.4%) 0/39 (0%) 29/39 (74.4%)
18 16/52 (30.8%) 10/52 (19.2%) 1/40 (2.5%) 23/41 (56.1%)
24 15/55 (27.3%)* 4/55 (7.3%) 0/42 (0%) 28/43 (65.1%)
36 18/59 (30.5%)* 4/59 (6.8%) 0/48 (0%) 41/48 (85.4%)
48 10/45 (22.2%) 4/45 (8.9%) 3/38 (7.9%) 23/38 (60.5%)
*p < 0.05 compared with native gliadin, Fisher’s exact test.
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Statistical analysis
All statistical analyses were performed by GraphPad
Prism version 5 (GraphPad Software, San Diego, CA,
USA). The Mann–Whitney U-test was used to
compare the median levels of tTGA at the time of
seroconversion between children not biopsied and/or
turned seronegative and children with biopsy-proven
CD. The Mann–Whitney U-test was also used to
compare the frequency of positive CD4+ T-cell
responses to deamidated and native gliadin during
the follow-up (Figure 2A), the percentage of memory
cells among proliferating CD4+ T cells stimulated
with deamidated or native gliadin (Figure 2B) and
the frequency of b7high cells among dividing memory
T cells stimulated with deamidated and native gliadin
compared with tetanus toxoid (Figure 2C). Fisher’s
exact test was used to compare the cumulative
incidences of tTGA seropositivity between girls and
boys and to assess the frequency of CD4+ T-cell
responses to deamidated compared with native
gliadin (Table I). p-Values of <0.05 were considered
signiﬁcant.
Results
Incidence of tTGA-seropositivity and celiac disease
Serum tissue transglutaminase IgA antibodies
(tTGA) were determined at all sampling points start-
ing from 12 months of age until the age of 36 or
48 months, and also at the age of 9 months in
41 children. Altogether, 19 children turned seropos-
itive for tTGA (6.5%) during the follow-up (Figure 1).
The median age at seroconversion was 24 months
(range 18–48 months). Ten of the tTGA-positive
children underwent duodenal biopsy and nine of
these were diagnosed with CD (90%). The median
age at the time of diagnosis was 3.5 years (2.6–
4.2 years). In eight of the nine (88.9%) children
with CD, the positive tTGA result in the follow-up
was the initial ﬁnding resulting in further serological
screening and clinical examination. Seven of these
children subsequently developed gastrointestinal
symptoms, such as runny stools, abdominal disten-
sion and abdominal pain before the duodenal biopsy,
and only one of the diagnosed children was
completely asymptomatic. Only one of the nine chil-
dren with CD was examined due to the clinical
suspicion of CD outside the study protocol. This
child was tTGA seronegative at the age of 24 months
but was later symptomatic and turned tTGA sero-
positive. CD was conﬁrmed with the duodenal biopsy
just before the age of 36 months. The cumulative
frequency of tTGA seropositivity and the age at diag-
nosis of CD are shown in Figure 3. The one child with
negative duodenal biopsy turned tTGA seronegative
during the follow-up. Nine of the tTGA-seropositive
children were not biopsied and seven of them had
transient tTGA seropositivity, as they converted back
to tTGA seronegative during the follow-up. In two
children, no further information was available and for
clarity, we have excluded these subjects from further
analyses of the group of transient tTGA-seropositive
children (a total 8 of 291, 2.7%). The median level of
tTGA at the time of seroconversion was signiﬁcantly
lower in the children not biopsied and/or turned
Figure 3. The cumulative percentage of tTGA seropositivity and the
incidence of celiac disease during the follow-up.
Table II. Development of anti-DGP antibodies before tTGA seroconversion.
Anti-DGP antibody
positivity
Transiently tTGA
seropositive (n = 8)
Months before;
median (range)
tTGA seropositive
with conﬁrmed
CD (n = 9)
Months before;
median (range)IgA IgG IgA IgG
At tTGA seroconversion 0 5 9 9
At least once before
tTGA seropositivity
0 4 14 (6–24) 1 5 12 (6–18)
‡2 times before tTGA
seropositivity
0 2 17 (9–24) 0 0
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seronegative than in children with biopsy-proven CD
(p = 0.004, median 9.6 and 100.0 IU, respectively,
Mann–Whitney U-test). The cumulative incidence of
tTGA seropositivity was signiﬁcantly higher in girls
than in boys (12.5% and 0.68%, respectively,
p < 0.0001, Fisher’s exact test) and all of the children
diagnosed with CD were girls.
Development of anti-DGP antibodies
All except one of the children (18 of 19, 91.7%) who
converted tTGA seropositive were also positive for
anti-DGP antibodies at least at one sampling point
using the earlier determined cut-off values 153 IU for
IgA and 119 IU for IgG class anti-DGP antibodies
[12]. All of the tTGA-seropositive children with con-
ﬁrmed CD (9 of 9, 100%) were both IgA and IgG
anti-DGP positive at the time point of tTGA sero-
conversion. In contrast, only ﬁve of the eight children
(62.5%) with transient tTGA seropositivity were anti-
DGP IgG positive at tTGA seroconversion and none
of these children were positive for IgA anti-DGP
(Table II).
Among children who remained tTGA seronegative
during the follow-up, some developed IgA or IgG
class anti-DGP. The percentage of IgA and IgG
anti-DGP positivity in tTGA seronegative children
during the follow-up varied between 0.4–1.4% and
4.1–10.0% at different time points, respectively
(Figure 4A and B). Most of the tTGA seronegative
children who developed anti-DGP positivity during
the follow-up were positive only at a single sampling
point and turned seronegative in the subsequent
sample (36 of 272, 13.2%). Only 20 of 272 children
(7.4%) were repeatedly IgA or IgG anti-DGP positive
(at least in two sampling points), and half of them
(10 of 272, 3.7%) were IgA or IgG anti-DPG positive
at the last sampling point. The median levels of
Figure 4. The frequency of IgA (A) and IgG (B) anti-DGP seropositivity and median levels of IgA (C) and IgG (D) anti-DGP antibodies at
different sampling points in children with transient tTGA seropositivity (tTGA + CD-), in tTGA-positive children with conﬁrmed CD
(tTGA + CD+) and in children who remained tTGA seronegative (tTGA-) throughout the follow-up.
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anti-DGP antibodies in children with transient tTGA
seropositivity, in tTGA-positive children who devel-
oped CD and in children remaining tTGA-
seronegative are shown in Figure 4C and D.
IgG-class anti-DGP antibodies precede tTGA
seroconversion in children with CD
In the group of tTGA-seropositive children with
conﬁrmed CD IgG anti-DGP positivity preceded
tTGA seroconversion in over half of the cases (5 of
9, 55.6%) a median 12 months earlier (Table II). In
one of the CD children also IgA anti-DGP antibodies
appeared 12 months earlier than tTGA-seropositivity.
Similarly, in the group of children with transient
tTGA seropositivity IgG anti-DGP preceded tTGA
seroconversion in 4 of the 8 subjects (50.0%) a
median 14 months earlier (Table II). Two of the
children with transient tTGA seropositivity were
IgG anti-DGP positive at two previous sampling
points before tTGA seroconversion (Table II).
T-cell responses to deamidated and native gliadin
Peripheral blood antigen-speciﬁc CD4+ T-cell
responses were studied in 85 children (39 girls and
46 boys) using a sensitive CFSE dilution-based
in vitro proliferation assay (Table I). A total of
309 samples were studied. The frequency of T-cell
responses to deamidated gliadin (gTG) was higher
than that to native gliadin at all time points (Table I
and Figure 2A). The highest frequency of positive
responses to gTG was 40.5% (17 of 42) at the age of
9 months, and thereafter the percentage of positive
gTG responses decreased during the course of sam-
pling to the level of 22.2% (10 of 45) at the age of
48 months (Table I and Figure 2A). The frequency of
positive responses to native gliadin declined even
more compared with gTG, from the level of 20%
to the level of 7–9% already at the age of 24 months
(Table I and Figure 2A).
Memory and naïve CD4+ T cells in the peripheral
blood can be distinguished by their mutually exclusive
expression of the CD45RO and CD45RA isoforms,
respectively. We analyzed the expression of CD45RA
and CD45RO molecules to determine the frequency
of memory phenotype T cells (CD45RA-CD45RO+)
within the proliferating antigen-speciﬁc CD4+ T cells,
as previously described [17]. The percentage of
CD45RA-CD45RO+ cells among proliferating
CD4+ T cells stimulated with deamidated gliadin
and native gliadin did not differ. The percentage of
CD45RA-CD45RO+ cells among proliferating
gTG-stimulated CD4+ T cells was signiﬁcantly higher
at the last sampling point, 48 months of age, than at
9 months, demonstrating an increase in the frequency
of responding memory CD4+ T cells with age (median
81% and 92%, respectively, p = 0.003,Mann–Whitney
U-test). The expression of b7-integrin, a gut-homing
molecule, was also analyzed in proliferating memory
CD4+ T cells [17]. The frequency of b7high cells was
higher among the dividing CD4+CD45RO+ memory
T cells stimulated with both gTG (median 45.3%) and
native gliadin (46.3%) compared with the memory
T cells stimulated with tetanus toxoid (median
29.7%) (p < 0.0001 and p = 0.0002, respectively,
Mann–Whitney U-test) (Figure 2C). The higher
expression of b7-integrin demonstrates that memory
CD4+ T cells speciﬁc to both deamidated and native
gliadin home to the gut where they have presumably
been primed.
Discussion
In this study, our aim was to analyze the development
of gliadin-speciﬁc immune responses in children with
a high genetic risk for CD and to determine whether
these could be detected before the clinical onset of the
disease by using immunological tests.
The cumulative incidence of tTGA seropositivity
by the age of 4 years was 6.5%, which is in accordance
with earlier studies where tTGA seropositivity in
genetically predisposed children has been reported
to vary between 2.6% and 6.0% by the age of 5–7 years
[23–25]. The cumulative incidence of conﬁrmed
CD was 3.1%. All except one of the children with
biopsy-conﬁrmed CD were diagnosed after tTGA
seropositivity during the follow-up without previous
clinical suspicion. There were three children who
seroconverted tTGA-positive at the age of 18 months.
Interestingly, eight children with transient tTGA
seropositivity, one of which also had a negative biopsy,
had signiﬁcantly lower tTGA titters at the time of
seroconversion than the nine children later conﬁrmed
with CD. In a large Finnish DIPP follow-up study, the
earliest seropositivity to tTGA has been reported to be
at the age of 12 months [24]. Since in that study
only 4 out of the 1320 children studied turned
tTGA-seropositive that early, it seems that tTGA-
seropositivity in children younger than 2 years is
extremely rare. As described above, 8 of all 291
children (2.7%) studied here had transient tTGA-
seropositivity and they turned tTGA-seronegative
during the follow-up. Although it is known that
clinically insigniﬁcant transient tTGA-seropositivity
may occur in small children without gluten-free
diet, ﬂuctuating tTGA seropositivity may in some
cases also precede the development of CD at later
stage [24].
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Several studies have demonstrated that anti-DGP
antibodies perform with both high sensitivity and
speciﬁcity in the diagnosis of CD both in adults
and children [26–28]. Analogously, we have demon-
strated earlier that our TR-IFMA anti-DGP assay
performs with high sensitivity and speciﬁcity in pedi-
atric patients [12]. Also in this prospective study, all of
the tTGA seroconverted children with conﬁrmed CD
were both IgA and IgG anti-DGP positive at the time
of tTGA seroconversion (Table II). Over half of the
children with transient tTGA seropositivity were also
IgG anti-DGP positive at the time of tTGA serocon-
version but none of them were IgA anti-DGP positive,
demonstrating the high speciﬁcity of IgA class
anti-DGP assay for CD, as we have observed also
earlier [12].
Not only tTGA seroconverted children, but also
some of the children who remained tTGA seroneg-
ative developed anti-DGP antibodies. Altogether
76 of 1151 serum samples analyzed from children
who remained tTGA seronegative during the
follow-up were positive for IgG and only 17 for IgA
anti-DGP, corresponding to calculated speciﬁcities of
93.4% and 98.5% for IgG and IgA anti-DGP, respec-
tively. Since the follow-up time was limited we do not
know whether some of the tTGA seronegative chil-
dren repeatedly positive for anti-DGP will develop
CD at a later stage. We can expect that the incidence
of CD in these children at high genetic risk will remain
at the same level than was the incidence during the
follow-up [5,24] A full evaluation of the signiﬁcance
of anti-DGP seropositivity would require a lengthy
follow-up until adulthood.
IgA class anti-DGP positivity preceded tTGA sero-
conversion only in one child with conﬁrmed CD,
whereas in over half of the children with conﬁrmed
CD IgG class anti-DGP antibodies appeared a
median 12 months earlier than tTGA seroconversion
(Table II). The results of our prospective study con-
cur with those of previous retrospective studies
[11,12], which demonstrate that IgG anti-DGP sero-
positivity precedes tTGA-seropositivity. However, in
the current study a similar phenomenon was observed
in children with transient tTGA seropositivity. There-
fore, IgG anti-DGP antibodies have a good sensitivity
to predict tTGA seropositivity but appear not to
clearly discriminate between CD-associated and tran-
sient tTGA seropositivity, potentially hindering the
clinical usefulness of the phenomenon.
In the present study, we also followed prospectively
the development of peripheral blood gliadin-speciﬁc
T-cell responses in early childhood. We have
demonstrated previously that CD4+ T cells speciﬁc
to deamidated gliadin can be detected at a higher
frequency in the peripheral blood of pediatric patients
at the time of CD diagnosis [17]. Liu et al. have also
demonstrated that gliadin-speciﬁc T-cell responses
can be detected without gluten challenge in peripheral
blood of children with CD [18]. However, there are
no prospective follow-up studies of CDwhere gliadin-
speciﬁc T-cell responses have been monitored in
children. Here, altogether 85 children were studied
for T-cell responses by using a sensitive CFSE-
dilution method [17,22]. T-cell responses to deami-
dated gliadin were detected at a higher frequency
than those to native gliadin at all time points in
HLA-DQ2-positive children, as reported also previ-
ously in children with CD [17]. Our previous and
current results are consistent with the idea that dea-
midation of gliadin epitopes enhances their T-cell
reactivity in the context of HLA-DQ2 [13]. Interest-
ingly, the highest frequency of T-cell responses to
both deamidated gliadin and native gliadin was
observed at the age of 9 months and the frequency
decreased during the follow-up. The frequency of
gTG-speciﬁc T-cell responses at the age of 48 months
(22.2%) was similar to what we have previously
reported (22.4%) in healthy children with HLA-
associated genetic risk for CD [17]. The high rate
of T-cell responses both to deamidated and native
gliadin in the earliest samples could be associated with
early immunization to dietary gluten, which in most
cases does not result in an antibody response to
deamidated gliadin. Of note, IgG class antibody
responses to whole gliadin are also commonly
observed in young children, and they are not always
associated with the development of CD [29,30], sup-
porting the concept that not all observed immune
responses to dietary gluten are pathogenic. We did not
directly test whether the observed gTG-speciﬁc T-cell
responses were frommemory origin or were restricted
by HLA-DQ2. However, staining for CD45RA and
CD45RO suggested that in children positive for
HLA-DQ2 CD4+ T cells speciﬁc to deamidated
and native gliadin have mainly a memory phenotype.
No differences in the frequency of memory CD4+
T cells were observed between gTG and native
gliadin-stimulated cultures, which are in accordance
with our earlier results in healthy controls carrying the
CD-related HLA-risk alleles [17]. The percentage of
CD45RA-CD45RO+ memory T cells in gTG-
stimulated cultures was highest at the last sampling
point, supporting the hypothesis the immune
response to gTG matures with age. The expression
of the gut-homing b7-integrin was signiﬁcantly higher
among proliferating memory T cells stimulated with
either gTG or native gliadin than those stimulated
with tetanus toxoid. No differences in the expression
of b7-integrin were detected between proliferating
memory T cells stimulated with gTG and native
Development of gliadin-speciﬁc immune responses 175
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
els
ink
i] 
at 
00
:09
 04
 M
ay
 20
16
 
gliadin, which is also in line with the earlier results
demonstrated in healthy controls [17]. These ﬁndings
support the hypothesis that the CD4+ T cells speciﬁc
to gliadin are generated in the intestinal mucosa and
are capable of homing back to the intestine after
circulating in peripheral blood. Based on our current
data, we cannot ascertain whether the emergence of
gliadin-speciﬁc T-cell responses is associated with the
introduction of gluten to diet since we did not analyze
blood samples taken before 9 months of age. Taken
together, our results indicate that peripheral blood
gliadin-speciﬁc T-cell responses are relatively com-
mon in HLA-DQ2-positive children and appear not
to be directly associated with the development of CD.
Oral tolerance to dietary antigens develops early in
life, and CD can be comprised either as a failure to
develop oral tolerance to gluten or as a later loss of the
tolerance [31]. Peripheral blood T-cell responses to
gliadin and gTG may therefore probably reﬂect the
early immunization and subsequent development of
T-cell tolerance to dietary gluten at early infancy.
In summary, we have followed prospectively the
emergence of both tTGA and anti-DGP seropositivity
in a cohort of children with a high genetic risk for CD
until the age of 4 years. Most of the children who
developed CD during the follow-up were diagnosed
due to a positive tTGA-result in the serological
screening without previous clinical suspicion. In
line with previous retrospective studies, we demon-
strate that anti-DGP antibodies may precede tTGA
seroconversion and thus may allow earlier detection
of CD. We also followed prospectively circulating T-
cell responses to deamidated gliadin and demonstrate
for the ﬁrst time that these responses are very com-
mon already at an early age of 12 months in HLA-
DQ2-positive children.
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